AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie skyrizi (risankizumab) — U.S. net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2025
15,202
Period ended Dec 31, 2025
Change on a year earlier
+50.7%
10,086 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Skyrizi (risankizumab) — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15,202 | +50.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 10,086 | +49.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 6,753 | +50.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 4,484 | +80.4% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 2,486 | +79.5% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 1,385 | +345.3% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 311 | – | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2020-02-21) ↗ |
Breakdown
What makes up skyrizi (risankizumab) — u.s. net revenues ($m)
Cite this data
StockData. (2026). AbbVie Skyrizi (risankizumab) — U.S. net revenues ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/skyrizi_us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.